McKesson Specialty Distribution LLC awarded $203.9M contract for centralized vaccine distribution

Contract Overview

Contract Amount: $203,868,411 ($203.9M)

Contractor: Mckesson Specialty Distribution LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2024-02-01

End Date: 2027-01-31

Contract Duration: 1,095 days

Daily Burn Rate: $186.2K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: CENTRALIZED VACCINE DISTRIBUTION

Place of Performance

Location: MEMPHIS, SHELBY County, TENNESSEE, 38115

State: Tennessee Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $203.9 million to MCKESSON SPECIALTY DISTRIBUTION LLC for work described as: CENTRALIZED VACCINE DISTRIBUTION Key points: 1. Contract value represents a significant investment in national vaccine supply chain resilience. 2. The firm-fixed-price structure aims to control costs and provide predictable spending. 3. A single award suggests a highly specialized service requirement or limited market capacity. 4. The contract duration of three years allows for sustained operational support. 5. Performance will be monitored by the Centers for Disease Control and Prevention (CDC). 6. This award is part of broader federal efforts to ensure public health preparedness.

Value Assessment

Rating: good

The contract value of $203.9 million over three years for centralized vaccine distribution appears reasonable given the critical nature of the service. Benchmarking against similar large-scale pharmaceutical distribution contracts is challenging without more specific service details, but the scale suggests a significant operational footprint. The firm-fixed-price type indicates a focus on cost certainty for the government, which is a positive indicator for value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. The fact that it resulted in a single award suggests that McKesson Specialty Distribution LLC was the most advantageous offer based on the evaluation criteria, potentially due to specialized capabilities, existing infrastructure, or competitive pricing. The level of competition, while resulting in one award, likely drove competitive proposals.

Taxpayer Impact: Full and open competition generally benefits taxpayers by fostering a competitive environment that can lead to better pricing and service quality. Even with a single award, the initial competition ensures that the government explored the market thoroughly.

Public Impact

The primary beneficiaries are the public, through ensured access to vaccines. Services delivered include the secure storage, handling, and distribution of vaccines nationwide. The geographic impact is national, covering all states and territories requiring vaccine access. Workforce implications include potential support roles within McKesson's distribution network and related logistics sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single distributor for a critical national resource.
Geographic concentration of distribution hubs could pose risks during regional emergencies.
Dependence on McKesson's internal supply chain management and potential vulnerabilities.

Positive Signals

McKesson's established track record in pharmaceutical distribution provides a degree of reliability.
The firm-fixed-price contract offers cost predictability for the government.
The CDC's oversight is expected to ensure adherence to stringent quality and safety standards.

Sector Analysis

This contract falls within the broader healthcare and logistics sector, specifically focusing on pharmaceutical distribution. The market for large-scale, centralized vaccine distribution is highly specialized, dominated by a few major players with extensive cold chain infrastructure and regulatory compliance expertise. The total federal spending on pharmaceutical distribution services is substantial, with contracts like this forming a critical component of public health infrastructure.

Small Business Impact

There is no indication of a small business set-aside for this contract. Given the specialized nature and scale of centralized vaccine distribution, it is unlikely that small businesses would be primary awardees for the prime contract. However, McKesson may engage small businesses for subcontracting opportunities in areas such as transportation, warehousing, or support services, though this is not explicitly detailed in the award data.

Oversight & Accountability

Oversight will be provided by the Centers for Disease Control and Prevention (CDC), a key agency within the Department of Health and Human Services. The contract type (firm-fixed-price) and definitive contract structure imply clear deliverables and payment terms. Transparency is facilitated through federal contract databases, and the CDC's program offices are responsible for monitoring performance and ensuring compliance with all contractual obligations.

Related Government Programs

Strategic National Stockpile (SNS)
Vaccine and Immunization Programs
Public Health Emergency Preparedness
Pharmaceutical Supply Chain Management

Risk Flags

Supply Chain Vulnerability
Cold Chain Integrity Risk
Single Point of Failure Potential
Geographic Distribution Challenges

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $203.9 million to MCKESSON SPECIALTY DISTRIBUTION LLC. CENTRALIZED VACCINE DISTRIBUTION

Who is the contractor on this award?

The obligated recipient is MCKESSON SPECIALTY DISTRIBUTION LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $203.9 million.

What is the period of performance?

Start: 2024-02-01. End: 2027-01-31.

What is McKesson Specialty Distribution LLC's prior experience with large-scale federal vaccine distribution contracts?

McKesson Specialty Distribution LLC has a significant history of managing complex pharmaceutical supply chains, including prior involvement in federal programs related to vaccine distribution. While specific details of past federal vaccine contracts are not provided in this data, McKesson is a major player in the pharmaceutical wholesale and distribution market, holding numerous contracts with government agencies and private entities. Their experience typically includes managing cold chain logistics, inventory control, and regulatory compliance for a wide range of pharmaceutical products, which are essential for vaccine handling. The scale of this current award suggests a reliance on their established infrastructure and proven capabilities in managing national distribution networks.

How does the $203.9 million contract value compare to historical federal spending on similar vaccine distribution services?

Direct comparison of the $203.9 million value to historical federal spending on *identical* centralized vaccine distribution services is difficult without more granular data on past contracts, such as specific volumes, service levels, and contract durations. However, the amount is substantial and reflects the significant logistical and operational requirements for a national vaccine distribution program. Federal spending on pharmaceutical distribution, including for programs like the Strategic National Stockpile and routine immunization initiatives, has historically been in the hundreds of millions of dollars annually. This award appears to be a significant component of the CDC's ongoing efforts to maintain a robust and responsive vaccine supply chain, consistent with the scale of national public health needs.

What are the primary performance risks associated with this centralized vaccine distribution contract?

Key performance risks include potential disruptions to the supply chain (e.g., transportation delays, weather events, or infrastructure failures), challenges in maintaining the required cold chain integrity for sensitive vaccines, and cybersecurity threats to distribution management systems. There's also a risk associated with the concentration of distribution capabilities with a single provider, which could exacerbate issues if McKesson faces operational challenges. Ensuring timely delivery to diverse geographic locations and managing fluctuating demand based on public health needs also present significant logistical risks that require robust contingency planning and continuous monitoring by the CDC.

What is the expected effectiveness of this contract in ensuring national vaccine availability during a public health emergency?

This contract is expected to be highly effective in ensuring national vaccine availability, particularly during public health emergencies. By centralizing distribution through a single, experienced provider like McKesson, the CDC can streamline logistics, improve inventory management, and ensure rapid deployment of vaccines across the nation. The firm-fixed-price structure incentivizes efficient operations, and McKesson's established infrastructure is designed to handle large volumes and maintain critical cold chain requirements. The three-year duration allows for sustained readiness and refinement of distribution protocols, contributing to a more resilient national response capability.

What are the historical spending patterns for vaccine distribution by the CDC or HHS?

Historical spending patterns for vaccine distribution by the CDC and HHS have generally involved significant, multi-year contracts with major pharmaceutical distributors. While specific figures fluctuate based on public health needs, pandemic responses, and immunization campaign scales, the CDC consistently allocates substantial funds to ensure the availability and distribution of vaccines. This includes funding for the Vaccines for Children (VFC) program and emergency preparedness initiatives. Annual spending on vaccine procurement and distribution can range from hundreds of millions to over a billion dollars, depending on the scope of programs and national health priorities. This $203.9 million award fits within this established pattern of significant federal investment in vaccine logistics.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: SUPPORT SVCS (PROF, ADMIN, MGMT) › ADMINISTRATIVE SUPPORT SERVICES

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75D301-23-R-72522

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Mckesson Corporation

Address: 4100 QUEST WAY, MEMPHIS, TN, 38115

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $8,115,420,400

Exercised Options: $326,018,000

Current Obligation: $203,868,411

Actual Outlays: $86,528,118

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline